← FDA DRUG APPROVALS

FDA ANDA · ANDA079089

BICALUTAMIDE

Sponsor: ADAPTIS

APPLICATION
ANDA079089
TYPE
ANDA
ORIGINAL APPROVAL
2009-07-06
LATEST ACTION
2025-01-03
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

BICALUTAMIDEPrescription
BICALUTAMIDE 50MG · TABLET · ORAL

Approval history

2025-01-03Manufacturing (CMC) · Supplement 6 · unknownAP
2019-04-16Labeling · Supplement 5 · standardAP
2019-04-16Labeling · Supplement 4 · standardAP
2012-07-19Labeling · Supplement 3 · standardAP
2012-06-21Labeling · Supplement 2AP
2011-10-14Labeling · Supplement 1AP
2009-07-06OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →